Sanofi licenses technology for new TB vaccine

Sanofi Pasteur has struck a licensing deal with the Statens Serum Institut of Denmark covering the use of its technology for a new tuberculosis vaccine. The pact includes SSI's Intercell IC31 adjuvant and the use of certain fusion proteins. SSI TB vaccine candidates are recombinant protein sub-units, including one currently in a Phase I clinical trial. Results from a previous study showed the SSI TB vaccine technology provided a positive immune response. TB kills two million people a year. 

"This agreement is a milestone for Sanofi Pasteur," said Wayne Pisano, president and CEO of Sanofi Pasteur, which is also working to develop a vaccine against another one of the biggest global infectious disease killers--malaria. "The current medical arsenal is inadequate for fighting tuberculosis."

- read the press release

Related Articles:
New compounds in works for tuberculosis. Report
Maxygen, Sanofi Pasteur ink $24.5M vaccine deal. Report
New approach to vaccine development. Report

Suggested Articles

Novavax has inked a $60 million contract with the U.S. Department of Defense to help fund U.S.-based manufacturing of its COVID-19 vaccine candidate.

Since the Warp Speed selections went public, experts have been wondering why some drugmakers were left off.

A few years ago, one of our Fierce editors met a Big Pharma R&D chief for the first time. “You’re the ones with the scary name,” he joked.